Lantern Pharma announced it will host an investor, analyst and shareholder briefing on April 9, 2026, at 8:30 a.m. Eastern, featuring a live demonstration of withZeta.ai, described as the first multi-agentic AI co-scientist for rare cancer drug discovery, development and clinical trial design. The webcast will highlight the platform’s capabilities, commercial architecture, competitive positioning and revenue strategy, alongside an overview of the rare cancer market opportunity and Lantern’s growth roadmap, with participation from CEO Panna Sharma and Chief Scientific Officer Kishor Bhatia.
This announcement is significant as it showcases a potentially transformative approach to oncology drug development. Lantern Pharma is an AI-driven company focused on transforming the cost, pace, and timeline of oncology drug discovery and development. The company's proprietary AI and machine learning platform, RADR®, leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve real-world problems in oncology drug development. The demonstration of withZeta.ai represents an evolution of this capability, specifically targeting the challenging area of rare cancers.
The implications of this technology are substantial for the pharmaceutical industry and patient care. By harnessing the power of AI, Lantern has accelerated the development of its growing pipeline of drug candidates that span multiple cancer indications, including both solid tumors and blood cancers and an antibody-drug conjugate program. On average, the company's newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2–3 years and at approximately $1.0–2.5 million per program. This contrasts sharply with traditional drug development, which often takes over a decade and costs billions.
Lantern's lead development programs include a Phase 2 clinical program and multiple planned Phase 1b/2a clinical trials. The company has also established a wholly-owned subsidiary, Starlight Therapeutics, to focus exclusively on the clinical execution of promising therapies for CNS and brain cancers. The AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD, indicating the significant commercial opportunity in addressing rare and complex cancers.
The upcoming briefing matters because it provides a transparent look at the operational and commercial potential of a platform aiming to democratize and accelerate cancer drug discovery. For more information on the company's developments, the latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN. The event underscores a strategic move to demonstrate tangible progress in AI-driven drug development to the investment community, potentially setting a new benchmark for efficiency in the field.
